Phapros Tbk PT (PEHA) - Cash Flow Conversion Efficiency

Latest as of March 2026: 0.064x

Based on the latest financial reports, Phapros Tbk PT (PEHA) has a cash flow conversion efficiency ratio of 0.064x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rp27.30 Billion ≈ $1.60 Million USD) by net assets (Rp428.24 Billion ≈ $25.09 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PEHA net asset quality score to measure how much of total assets are equity-financed.

Phapros Tbk PT - Cash Flow Conversion Efficiency Trend (2011–2025)

This chart illustrates how Phapros Tbk PT's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Phapros Tbk PT (PEHA) cash flow quality to evaluate the quality of earnings relative to operating cash generation.

Phapros Tbk PT Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Phapros Tbk PT ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Chinyang Poly
KO:010640
0.004x
Tier One Silver Inc
V:TSLV
-0.161x
Ihlas Yayin Holding A.S.
IS:IHYAY
0.011x
Integritas Viager SA
PA:MLVIE
N/A
17 Education Technology Group Inc
NASDAQ:YQ
-1.269x
Kier Group PLC
LSE:KIE
0.457x
Tempest Security AB
ST:TSEC
0.232x
MYMBN Berhad
KLSE:0280
-0.036x

Annual Cash Flow Conversion Efficiency for Phapros Tbk PT (2011–2025)

The table below shows the annual cash flow conversion efficiency of Phapros Tbk PT from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see Phapros Tbk PT market cap and net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 Rp427.47 Billion
≈ $25.05 Million
Rp70.98 Billion
≈ $4.16 Million
0.166x -53.79%
2024-12-31 Rp393.12 Billion
≈ $23.04 Million
Rp141.28 Billion
≈ $8.28 Million
0.359x +2016.64%
2023-12-31 Rp770.33 Billion
≈ $45.14 Million
Rp-14.44 Billion
≈ $-846.35K
-0.019x -151.56%
2022-12-31 Rp771.82 Billion
≈ $45.23 Million
Rp28.07 Billion
≈ $1.64 Million
0.036x -85.81%
2021-12-31 Rp740.98 Billion
≈ $43.42 Million
Rp189.92 Billion
≈ $11.13 Million
0.256x -26.81%
2020-12-31 Rp740.91 Billion
≈ $43.41 Million
Rp259.48 Billion
≈ $15.20 Million
0.350x +11694.31%
2019-12-31 Rp821.61 Billion
≈ $48.14 Million
Rp-2.48 Billion
≈ $-145.42K
-0.003x +96.86%
2018-12-31 Rp789.80 Billion
≈ $46.28 Million
Rp-75.91 Billion
≈ $-4.45 Million
-0.096x -166.07%
2017-12-31 Rp701.39 Billion
≈ $41.10 Million
Rp102.03 Billion
≈ $5.98 Million
0.145x -20.68%
2016-12-31 Rp622.08 Billion
≈ $36.45 Million
Rp114.08 Billion
≈ $6.68 Million
0.183x +17.67%
2015-12-31 Rp449.72 Billion
≈ $26.35 Million
Rp70.09 Billion
≈ $4.11 Million
0.156x -24.29%
2014-12-31 Rp408.25 Billion
≈ $23.92 Million
Rp84.04 Billion
≈ $4.92 Million
0.206x +313.18%
2013-12-31 Rp391.40 Billion
≈ $22.93 Million
Rp19.50 Billion
≈ $1.14 Million
0.050x -67.11%
2012-12-31 Rp375.63 Billion
≈ $22.01 Million
Rp56.90 Billion
≈ $3.33 Million
0.151x +288.78%
2011-12-31 Rp339.17 Billion
≈ $19.87 Million
Rp-27.22 Billion
≈ $-1.59 Million
-0.080x --

About Phapros Tbk PT

JK:PEHA Indonesia Drug Manufacturers - Specialty & Generic
Market Cap
$13.09 Million
Rp223.44 Billion IDR
Market Cap Rank
#26337 Global
#583 in Indonesia
Share Price
Rp266.00
Change (1 day)
+0.76%
52-Week Range
Rp214.00 - Rp384.00
All Time High
Rp2996.89
About

PT Phapros Tbk, together with its subsidiaries, operates in the pharmaceutical industry in Indonesia. The company operates through Ethical; Over the Counter (OTC) Drugs; Generic Drugs Bearing (OCB); and Toll-in segments. It offers OTC drugs, including Antimo Anak, Antimo tablet, Livron B Plex, Becefort Sirop and tablet, Noza, Febrinex, Betafort suspensi, and Hemorogard. The company also provides … Read more